Yusri Elsayed

Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules

George D. Demetri, Sant P. Chawla, Margaret von Mehren et al. · Journal of Clinical Oncology · 2009 · 536 citations · Full text

Medicine, Oncology, Pharmacology +15

Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma

Qin Ryan, Donna Headlee, Milin Acharya et al. · Journal of Clinical Oncology · 2005 · 414 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

Kenneth J. Pienta, Jean-Pascal Machiels, Dirk Schrijvers et al. · Investigational New Drugs · 2012 · 399 citations

Medicine, Oncology, Pharmacology +17

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

Saad Z. Usmani, Alfred L. Garfall, Niels W.C.J. van de Donk et al. · The Lancet · 2021 · 312 citations

Medicine, Hematology, Immunology +12

A T-cell–redirecting bispecific G-protein–coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma

Kodandaram Pillarisetti, Suzanne C. Edavettal, Mark Mendonça et al. · Blood · 2020 · 163 citations · Full text

Medicine, Immunology, Oncology +17